This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MeadWestvaco Corporation (NYSE:
MWV), a global leader in
packaging and packaging solutions, announced today that it is expanding its leading position in adherence packaging with the acquisition of
AARDEX Group SA. AARDEX Group is the leader and pioneer in the design and use of electronic medication event monitoring systems and applications designed to measure, analyze, and manage patient adherence in clinical drug trials.
Bruce Thomas, president, MWV Healthcare and senior vice president, Global Innovation (Photo: Business Wire)
“This acquisition builds on MWV’s long-standing commitment and scientific approach to showing medication packaging’s impact as an important adherence intervention,” said Bruce Thomas, president, MWV Healthcare and Senior Vice President, Global Innovation. “We recognize the critical global need to create packaging solutions that address the issue of medication non-adherence. With the acquisition of AARDEX Group, MWV will now be able to provide customers with a complete range of packaging, data analysis and service solutions that address non-adherence to medications, from phase II clinical trials all the way through commercialization.”
AARDEX Group is led by scientists Dr. Bernard Vrijens and Dr. John Urquhart, who pioneered electronic medication event monitoring, now widely recognized as the gold-standard method for compiling patients’ drug dosing histories during clinical trials. A small microcircuit, integrated into the drug package, records the time and date of each opening of the package. This technology has been employed in over 500 clinical research studies conducted by leading universities, public and private research organizations, and numerous research-based pharmaceutical companies. AARDEX Group’s work has resulted in the publication of more than 550 research papers in peer-reviewed journals and as well as a vast knowledge base of patient adherence histories. More than 500,000 trial participants have used AARDEX Group’s products in such studies.